HYNR-CS-Allo ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	2

2. Amyotrophic lateral sclerosis

---

Clinical trials : 645 /  Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03214146 (ClinicalTrials.gov)	February 1, 2017	9/7/2017	Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS	An Open-label, Phase 1 Trial for Safety and Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell(HYNR-CS-Allo Inj) Treatment in Amyotrophic Lateral Sclerosis(ALS)	Amyotrophic Lateral Sclerosis	Biological: HYNRCS-Allo inj	Hanyang University Seoul Hospital	Corestem, Inc.	Active, not recruiting	25 Years	80 Years	All	6	Phase 1	Korea, Republic of
2	NCT01758510 (ClinicalTrials.gov)	December 2012	10/12/2012	Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis	An Open-label, Phase 1 Trial for Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell(HYNR-CS-Allo Inj) Treatment in Amyotrophic Lateral Sclerosis(ALS)	Amyotrophic Lateral Sclerosis;Motor Neuron Disease;Neuromuscular Disease;Neurodegenerative Disease;Central Nervous System Disease	Genetic: HYNR-CS-Allo	Hanyang University Seoul Hospital	Corestem, Inc.	Completed	25 Years	80 Years	All	6	Phase 1	Korea, Republic of